• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在兔颈静脉血栓形成模型中,静脉推注或输注组织型纤溶酶原激活剂诱导溶栓的时间进程。

Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.

作者信息

Clozel J P, Tschopp T, Luedin E, Holvoet P

机构信息

F. Hoffmann-La Roche & Co, Ltd, Pharmaceutical Research Department, Basel, Switzerland.

出版信息

Circulation. 1989 Jan;79(1):125-33. doi: 10.1161/01.cir.79.1.125.

DOI:10.1161/01.cir.79.1.125
PMID:2491972
Abstract

Tissue plasminogen activator is a thrombolytic agent that has been shown to be efficient in patients with myocardial infarction or pulmonary embolus. However, little is known about the time course and the dose dependency of its thrombolytic effect. The goal of our study was to investigate the time course of the thrombolysis induced by increasing doses of tissue plasminogen activator (t-PA) given either as a continuous infusion (0.0625-1 mg/kg) or as a bolus (0.05-0.4 mg/kg). For this purpose, we modified a previously described rabbit jugular vein thrombosis model by using an external gamma counter to follow continuously the thrombolysis. After administration of t-PA as either an infusion or a bolus, the rate and the extent of thrombolysis were dose dependent. The thrombus size decreased regularly following an exponential curve and reached a lower asymptote implicating an unlysable thrombus. As expected, after bolus injection, t-PA was rapidly inhibited resulting in a duration of action of approximately 15 minutes; this was independent of the dose. Surprisingly, during continuous infusion of t-PA for as long as 4 hours, the duration of action was limited to about 2 hours, although the plasma t-PA activity levels remained stable. Although the rate of inhibition was lower and thus the duration of action was longer during continuous infusion of t-PA than after a bolus injection, the extent of thrombolysis was similar when the same dose of t-PA was given as either a bolus or an infusion. These findings could be attributed to the higher initial rate of thrombolysis observed after a bolus injection.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

组织型纤溶酶原激活剂是一种溶栓剂,已证明对心肌梗死或肺栓塞患者有效。然而,关于其溶栓作用的时间进程和剂量依赖性知之甚少。我们研究的目的是调查通过持续输注(0.0625 - 1毫克/千克)或推注(0.05 - 0.4毫克/千克)给予递增剂量的组织型纤溶酶原激活剂(t - PA)所诱导的溶栓时间进程。为此,我们通过使用外部γ计数器持续跟踪溶栓过程,对先前描述的兔颈静脉血栓形成模型进行了改进。在给予t - PA输注或推注后,溶栓的速率和程度呈剂量依赖性。血栓大小按照指数曲线规律减小,并达到一个较低的渐近线,这意味着存在不可溶解的血栓。正如预期的那样,推注注射后,t - PA迅速被抑制,导致作用持续时间约为15分钟;这与剂量无关。令人惊讶的是,在持续输注t - PA长达4小时的过程中,作用持续时间限制在约2小时,尽管血浆t - PA活性水平保持稳定。虽然持续输注t - PA时抑制速率较低,因此作用持续时间较长,但与推注相同剂量的t - PA相比,溶栓程度相似。这些发现可能归因于推注注射后观察到的较高的初始溶栓速率。(摘要截短于250字)

相似文献

1
Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.在兔颈静脉血栓形成模型中,静脉推注或输注组织型纤溶酶原激活剂诱导溶栓的时间进程。
Circulation. 1989 Jan;79(1):125-33. doi: 10.1161/01.cir.79.1.125.
2
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶序贯输注对兔颈静脉血栓形成模型溶栓的协同作用。
Thromb Haemost. 1987 Oct 28;58(3):943-6.
3
SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.SSR182289A增强了纤溶药物在兔静脉和动脉血栓形成模型中诱导的溶栓作用。
J Thromb Haemost. 2004 Apr;2(4):629-36. doi: 10.1111/j.1538-7836.2004.00687.x.
4
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
5
An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.活化凝血酶激活的纤维蛋白溶解抑制因子抑制剂在兔颈静脉溶栓模型中增强组织型纤溶酶原激活剂诱导的溶栓作用。
Thromb Res. 2000 May 15;98(4):333-42. doi: 10.1016/s0049-3848(00)00184-5.
6
Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.离子霉素V在兔颈静脉血栓形成模型中的溶栓作用。
Blood Coagul Fibrinolysis. 2001 Oct;12(7):521-9. doi: 10.1097/00001721-200110000-00003.
7
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.在大肠杆菌中产生的未糖基化重组组织型纤溶酶原激活剂(BM 06.021)的药代动力学和溶栓特性。
Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):108-13. doi: 10.1007/BF00167579.
8
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.单链尿激酶型纤溶酶原激活剂和组织型纤溶酶原激活剂在犬动脉血栓形成模型中的推注剂量反应特征。
Thromb Res. 1988 Nov 15;52(4):295-312. doi: 10.1016/0049-3848(88)90071-0.
9
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.用人外源性(组织型)纤溶酶原激活剂对实验性颈静脉血栓形成的家兔进行溶栓治疗。激活剂分子形式和剂量、血栓形成时间以及给药途径的影响
J Clin Invest. 1983 Feb;71(2):368-76. doi: 10.1172/jci110778.
10
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.嵌合组织型和尿激酶型纤溶酶原激活剂的溶栓及药代动力学特性
Circulation. 1991 Sep;84(3):1216-34. doi: 10.1161/01.cir.84.3.1216.

引用本文的文献

1
Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.无需辅助抗栓治疗实现最佳再灌注:新型溶栓给药策略
J Thromb Thrombolysis. 1995;1(3):269-277. doi: 10.1007/BF01060736.
2
Novel and Innovative Dosing Regimens in Thrombolytic Therapy for Acute Myocardial Infarction.急性心肌梗死溶栓治疗中的新型创新给药方案
J Thromb Thrombolysis. 1995;1(2):145-151. doi: 10.1007/BF01062571.
3
Pharmacokinetic optimisation of the treatment of deep vein thrombosis.深静脉血栓形成治疗的药代动力学优化
Clin Pharmacokinet. 1997 Feb;32(2):145-72. doi: 10.2165/00003088-199732020-00005.
4
Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.纤溶酶原-纤溶酶原激活剂嵌合体在光化学诱导血栓形成(PIT)模型中的溶栓作用。
Br J Pharmacol. 1993 Dec;110(4):1278-9. doi: 10.1111/j.1476-5381.1993.tb13954.x.
5
Advances in thrombolytic therapy.溶栓治疗的进展。
Cardiovasc Drugs Ther. 1992 Apr;6(2):111-24. doi: 10.1007/BF00054557.